Meeder Asset Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Meeder Asset Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,012	Closed	-$10K	–	2358
2019 Q2	$10K	Buy	2,012 +448	+29%	+$2.01K	﹤0.01%	1470
2019 Q1	$5K	Sell	1,564 -86	-5%	-$373	﹤0.01%	1419
2018 Q4	$10K	Buy	1,650 +1,076	+187%	+$6.57K	﹤0.01%	1265
2018 Q3	$3K	Buy	+574	New	+$2.87K	﹤0.01%	1423
2017 Q3	–	Sell	-263	Closed	-$2K	–	1828
2017 Q2	$2K	Sell	263 -584	-69%	-$3.59K	﹤0.01%	1469
2017 Q1	$4K	Sell	847 -26	-3%	-$176	﹤0.01%	1218
2016 Q4	$6K	Buy	+873	New	+$7.06K	﹤0.01%	847

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Meeder Asset Management's PETX Position: Q3 2019 in Review

Meeder Asset Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 2,012 shares — an estimated $10K sold.

Meeder Asset Management first reported a position in PETX in Q4 2016 and held it in 7 quarters. The position peaked at $10K in Q2 2019. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

Meeder Asset Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Meeder Asset Management sold 2,012 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $10K.
Meeder Asset Management first reported a position in Aratana Therapeutics, Inc. in Q4 2016 and held it in 7 quarters.
Meeder Asset Management's Aratana Therapeutics, Inc. position peaked at $10K in Q2 2019.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Meeder Asset Management's 13F filing for Q3 2019, filed 17 Oct 2019.